TrialJournal of diabetes investigation2022

Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.

Yumie Takeshita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.